Imatinib Completed Phase 2 Trials for Cancer, Ovarian / Primary Peritoneal Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00216112Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
NCT00510653Gleevec Study for Patients With Ovarian Cancer
NCT00928642Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer